Jonathan Edward Campbell

Associate Professor in Medicine

Appointments and Affiliations

Capozzi, ME; D'Alessio, DA; Campbell, JE, The past, present, and future physiology and pharmacology of glucagon., Cell Metab, vol 34 no. 11 (2022), pp. 1654-1674 [10.1016/j.cmet.2022.10.001] [abs].
Campbell, JE, Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms., Molecular Metabolism, vol 46 (2021) [10.1016/j.molmet.2020.101139] [abs].
El, K; Gray, SM; Capozzi, ME; Knuth, ER; Jin, E; Svendsen, B; Clifford, A; Brown, JL; Encisco, SE; Chazotte, BM; Sloop, KW; Nunez, DJ; Merrins, MJ; D'Alessio, DA; Campbell, JE, GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells., Science Advances, vol 7 no. 11 (2021) [10.1126/sciadv.abf1948] [abs].
Huynh, FK; Peterson, BS; Anderson, KA; Lin, Z; Coakley, AJ; Llaguno, FMS; Nguyen, T-TN; Campbell, JE; Stephens, SB; Newgard, CB; Hirschey, MD, β-Cell-specific ablation of sirtuin 4 does not affect nutrient-stimulated insulin secretion in mice., Am J Physiol Endocrinol Metab, vol 319 no. 4 (2020), pp. E805-E813 [10.1152/ajpendo.00170.2020] [abs].
Willard, FS; Douros, JD; Gabe, MB; Showalter, AD; Wainscott, DB; Suter, TM; Capozzi, ME; van der Velden, WJ; Stutsman, C; Cardona, GR; Urva, S; Emmerson, PJ; Holst, JJ; D'Alessio, DA; Coghlan, MP; Rosenkilde, MM; Campbell, JE; Sloop, KW, Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist., Jci Insight, vol 5 no. 17 (2020) [10.1172/jci.insight.140532] [abs].